济南我男人很快射精怎么办济南性生活射精过多,济南龟头炎会自愈么,济南包皮为什么老破,济南哪些能治早泄,济南较好男子医院,济南医治前列腺炎,济南中药早泄的调理

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

SAN FRANCISCO, Nov. 22 (Xinhua) -- Microsoft announced on Tuesday that it has acquired video search engine VideoSurf.In a press release, Microsoft said it will integrate VideoSurf' s technology across its entertainment platform to augment the Xbox 360 ecosystem and evolve search and discovery of entertainment content on Xbox LIVE.Details of the deal were not disclosed. Technology news site TechCrunch cited Israeli business newspaper Calcalist as saying that the company was bought for about 70 million U.S. dollars.The San Mateo, California-based company, founded by four Israelis in 2006, offers a technology that "sees" frames inside videos to make discovering content fast, easy and accurate.Since its founding, VideoSurf has raised 28 million dollars from several sources, including Facebook chief operating officer Sheryl Sandberg and her husband, as well as former U.S. vice president Al Gore.Last month, Microsoft announced that it will bring cable television content to its Xbox video game console over the holiday season, expanding the console into an entertainment hub.The software giant said Tuesday that the latest acquisition will make it easier for world-class video partners to take full advantage of advanced search features.

TAIPEI, Dec. 10 (Xinhua) -- A televised debate among three candidates for Taiwan's next deputy leader was staged Saturday, highlighting cross-Strait political and economic issues, for next month's Taiwan leader election.The three candidates touched upon topics such as stances on the reunification of Taiwan and the Chinese mainland and the "Taiwan independence," last year's signing of the cross-Strait Economic Cooperation Framework Agreement (ECFA), among other cross-Strait issues, during the second face-to-face debate before the Jan. 14, 2012 election.Wu Den-yih, who is incumbent Taiwanese leader Ma Ying-jeou's running mate and currently chief of Taiwan's executive authority, said the signing of the ECFA aims to "help people do business and enhance Taiwan's competitiveness." Ma is seeking a second term.The ECFA did not speed up Taiwan's inclination toward the mainland market, but ensured the island's utmost interests instead, Wu said, adding that if Ma, who is also chairman of Taiwan's ruling Kuomintang (KMT) party, did not win during the upcoming election, cross-Strait peace and stability would not be maintained.However, Wu's main rival Su Jia-chyuan, the running mate of Tsai Ing-wen who campaigned for Taiwan's next leader representing major opposition Democratic Progressive Party (DPP), claimed that Taiwan is a "sovereign state" and its fate would be decided by Taiwanese themselves, no matter it would become independent or unified with the mainland, or maintain the status quo.Taiwan's future would be guaranteed only if the so-called "Taiwan consensus," put forward by Tsai, was realized, Su said during the debate.Another debater, Lin Ruey-shiung, 72, the running mate of People First Party (PFP) candidate James Soong, called for the signing of a cross-Strait peace accord, and said that the Chinese nation was fundamentally one family, with reunification benefiting both and secession hurting both.Lin said, as a member of the Chinese nation, Taiwan must be reunified with the mainland in the future, without wars, and it is the aspiration of all Taiwanese that people of both sides could freely visit each other.The three candidates also debated on anti-corruption, financial deficit and social equity.Saturday's debate among the candidates for deputy leader was the second of a three-part series. A debate of the Taiwan leader hopefuls was staged last Saturday, and they will spar again on Dec. 17.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."